FUSIONSPROTEIN MIT IL13

European patent · EP3955955 · In force

Register entry

Publication number
EP3955955
Application number
EP20720425
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 17, 2020
Published
Feb 23, 2022
Granted
Feb 26, 2025
Protection ends at the latest
Apr 16, 2040
Next annual fee due
Apr 30, 2027
IPC classes
A61K 38/20 (2006.01)
A61P 25/02 (2006.01)
Priority
NL 2022982 19.04.2019
NL 2022984 19.04.2019
PCT application
PCT/EP2020/060910 17.04.2020
PCT publication
WO2020/212598 22.10.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 28, 2026

    Next annual fee due on

    Next annual fee due on
    30.04.2026 → 30.04.2027

    Published in Swissreg on 28.09.2026

  2. Jan 7, 2026

    Change

    Published in Swissreg on 07.01.2026

  3. May 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.04.2025 → 30.04.2026

    Published in Swissreg on 01.05.2025

  4. Mar 17, 2025

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach, 8027 Zürich

    Published in Swissreg on 17.03.2025

  5. Feb 26, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 26.02.2025

Parties

Holder

Synerkine Pharma B.V.

Galileiweg 8, 2333 BD Leiden, NL

Agent

Isler & Pedrazzini AG

Postfach, 8027 Zürich

Inventor

EIJKELKAMP, Niels

3584 CM UTRECHT, NL

HACK, Cornelis, Erik

3584 CM UTRECHT, NL

PRADO SANCHEZ, Judith

3584 CM UTRECHT, NL

POPOV- CELEKETIC , Jelena

3584 CM UTRECHT, NL

VERSTEEG, Sabine

3584 CM UTRECHT, NL

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.